Literature DB >> 18361427

Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer.

Yuanqing Ye1, Hushan Yang, H Barton Grossman, Colin Dinney, Xifeng Wu, Jian Gu.   

Abstract

BACKGROUND: Cell cycle checkpoint regulation is crucial for the prevention of carcinogenesis in mammalian cells.
METHODS: To test the hypothesis that common sequence variants in the cell cycle control pathway may affect bladder cancer susceptibility, the effects of a panel of 10 potential functional single nucleotide polymorphisms (SNPs) from 7 cell cycle control genes, P53, P21, P27, CDK4, CDK6, CCND1, and STK15, were evaluated on bladder cancer risk in a case-control study of 696 bladder cancer cases and 629 healthy controls.
RESULTS: Overall, on individual SNP analysis only individuals with the p53 intron 3 16-bp duplication polymorphism variant allele had a significantly reduced bladder cancer risk (odds ratio [OR] = 0.74, 95% confidence interval [CI], 0.56-0.96). This effect was more evident in former smokers and younger subjects. We then applied the Classification and Regression Tree (CART) statistical approach to explore the high-order gene-gene and gene-smoking interactions. In the CART analysis, smoking status was identified as the most influential factor for bladder cancer susceptibility. The final decision tree by CART contained 6 terminal nodes. Compared with the second-lowest risk group the ORs for terminal nodes 1 and 3 to 6 ranged from 0.46 to 6.30.
CONCLUSIONS: These results suggest that cell cycle genetic polymorphisms may affect bladder cancer predisposition through modulation of host genome stability and confirm the importance of studying gene-gene and gene-environment interactions in bladder cancer risk assessment. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361427     DOI: 10.1002/cncr.23472

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.

Authors:  Annemarie Koch; Jiri Hatina; Harald Rieder; Hans-Helge Seifert; Wolfgang Huckenbeck; Frank Jankowiak; Andrea R Florl; Robert Stoehr; Wolfgang A Schulz
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

2.  Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population.

Authors:  Ying-Xue Wang; Lei Zhao; Xiu-Yun Wang; Chang-Mei Liu; Su-Guo Yu
Journal:  Med Oncol       Date:  2011-11-26       Impact factor: 3.064

3.  Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal:  Mol Genet Genomics       Date:  2014-08-26       Impact factor: 3.291

4.  Association between glutathione S-transferase M1 null variant and risk of bladder cancer in Chinese Han population.

Authors:  Wei Xu; Fa Wang; Li Ying; Hong-Hui Wang
Journal:  Tumour Biol       Date:  2014-01

5.  Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk.

Authors:  Zhi-Hong Liu; Er-Dun Bao
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

6.  Association between the G870A polymorphism of Cyclin D1 gene and glioma risk.

Authors:  Hailiang Zong; Lei Cao; Chong Ma; Jianping Zhao; Xing Ming; Ming Shang; Hongsheng Xu
Journal:  Tumour Biol       Date:  2014-05-20

7.  Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Jing Zhu; Lei Lu; Xiang Cheng; Rongkai Xie; Zhengqiong Chen; Youfei Li; Guilan Lin; Jianmei Liu; Ying Yang
Journal:  Tumour Biol       Date:  2014-03-12

Review 8.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

9.  Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer.

Authors:  Eugene K Lee; Yuanquing Ye; Ashish M Kamat; Xifeng Wu
Journal:  Cancer       Date:  2013-03-25       Impact factor: 6.860

10.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.